Frontiers in Psychiatry
December 2, 2022
Torsten Passie, Jeffrey Guss, Rainer Krähenmann
71 citations
Lysergic acid diethylamide (LSD) and similar psychoactive drugs have been used in psychotherapy since 1949, when the first clinical study with lower-dose LSD showed therapeutically relevant effects. Psycholytic therapy, named in 1960, involved serial lower-dose LSD or psilocybin sessions within a psychoanalytical framework, conducted in clinical settings on both inpatient and outpatient bases. Over 15 years, it was established at 30 clinical treatment centers and by more than 100 outpatient psychotherapists in Europe, while North America favored high-dose psychedelic therapy. Professor Hanscarl Leuner in Germany was the leading figure, providing a detailed analysis of the LSD reaction in a 1962 monograph. The article reviews evidence for psycholytic therapy's efficacy and argues for its inclusion in substance-assisted psychotherapy.
European Psychiatry
March 1, 2015
Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann et al.
20 citations
Social cognition, including empathy and reactions to social exclusion, is often impaired in psychiatric disorders like depression but is poorly addressed by current treatments. In a double-blind, randomized, cross-over study with healthy volunteers, psilocybin (0.215 mg/kg) reduced the neural response to social exclusion in the anterior cingulate cortex, a brain region linked to social pain, compared to placebo. Emotional empathy was enhanced after psilocybin, while cognitive empathy showed no significant change. These findings suggest that 5HT-1A/2A receptor subtypes modulate socio-cognitive functioning and may be relevant for treating social cognition deficits, particularly in depressed patients.
European Neuropsychopharmacology
September 1, 2015
Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann et al.
6 citations
No Summary
European Neuropsychopharmacology
October 1, 2016
O. Grimm, Rainer Krähenmann, Katrin H. Preller et al.
1 citation
No Summary